Risk adjusted net present value: What is the current valuation of Spur Therapeutics’s FLT-201?
FLT-201 is a gene therapy commercialized by Spur Therapeutics, with a leading Phase II program in Gaucher Disease Type I.
FLT-201 is a gene therapy commercialized by Spur Therapeutics, with a leading Phase II program in Gaucher Disease Type I.
What's Your Reaction?
